Shanghai Medicilon Inc - Asset Resilience Ratio

Latest as of June 2026: 6.69%

Shanghai Medicilon Inc (688202) has an Asset Resilience Ratio of 6.69% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 688202 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥192.85 Million

≈ $28.22 Million USD Cash + Short-term Investments

Total Assets

CN¥2.88 Billion

≈ $421.57 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Shanghai Medicilon Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Shanghai Medicilon Inc (688202) total assets.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Medicilon Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 688202 total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥192.85 Million	6.69%
Total Liquid Assets	CN¥192.85 Million	6.69%

Asset Resilience Insights

Limited Liquidity: Shanghai Medicilon Inc maintains only 6.69% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Shanghai Medicilon Inc Industry Peers by Asset Resilience Ratio

Compare Shanghai Medicilon Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	16.06%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Celldex Therapeutics Inc NASDAQ:CLDX	Biotechnology	81.32%
MBX Biosciences, Inc. Common Stock NASDAQ:MBX	Biotechnology	87.20%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Savara Inc NASDAQ:SVRA	Biotechnology	68.30%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%

Annual Asset Resilience Ratio for Shanghai Medicilon Inc (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Shanghai Medicilon Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	4.33%	CN¥113.41 Million ≈ $16.59 Million	CN¥2.62 Billion ≈ $383.69 Million	-4.93pp
2024-12-31	9.25%	CN¥261.22 Million ≈ $38.23 Million	CN¥2.82 Billion ≈ $413.13 Million	-6.62pp
2023-12-31	15.87%	CN¥518.23 Million ≈ $75.83 Million	CN¥3.27 Billion ≈ $477.90 Million	+10.29pp
2021-12-31	5.58%	CN¥100.00 Million ≈ $14.63 Million	CN¥1.79 Billion ≈ $262.46 Million	--

pp = percentage points

About Shanghai Medicilon Inc

SHG:688202 China Biotechnology

Market Cap

$2.09 Billion

CN¥14.27 Billion CNY

Market Cap Rank

#6036 Global

#1161 in China

Share Price

CN¥106.20

Change (1 day)

+2.22%

52-Week Range

CN¥51.31 - CN¥110.00

All Time High

CN¥394.88